Evidence map›Paper›PMID 35135065›Full record

ArticleJournal of stroke2022

Apixaban for Secondary Stroke Prevention: Coexistant Cerebral Atherosclerosis May Increase Recurrent Strokes.

Jong S Kim, Jaseong Koo, Dong-Ick Shin, Byung-Su Kim, Jei Kim, Eung-Gyu Kim, Keun-Sik Hong, Hyeju Yi

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of stroke, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01885598 (Eliquis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01885598 completednot on this map

Eliquis (Apixaban) Regulatory Postmarketing Surveillance in Clinical Practice for Stroke Prevention in Nonvalvular Atrial Fibrillation

TypeobservationalSponsorBristol-Myers SquibbRan2013 to 2017Enrolled3,335ConditionsNonValvular Atrial FibrillationArmsApixaban
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Targeted drug delivery systems for atherosclerosis.Journal of nanobiotechnology · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Jong S KimDepartment of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jaseong KooDepartment of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Dong-Ick ShinDepartment of Neurology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
Byung-Su KimDepartment of Neurology, Bundang Jesaeng General Hospital, Daejin Medical Center, Seongnam, Korea.
Jei KimDepartment of Neurology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea.
Eung-Gyu KimDepartment of Neurology, Inje University Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea.
Keun-Sik HongDepartment of Neurology, Inje University Ilsan Paik Hospital, College of Medicine, Inje University, Goyang, Korea.
Hyeju YiBristol Myers Squibb Korea, Seoul, Korea.
Ulsan College · KRBristol-Myers Squibb (South Korea) · KRBundang Jesaeng Hospital · KRChungbuk National University Hospital · KRInje University Busan Paik Hospital · KRInje University Ilsan Paik Hospital · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KR

Funding

BMS KoreaBoryung PharmaceuticalBristol Myers SquibbDaiichi-SankyoDong-AHanmi PharmPfizerServierShin-Poong
6 · The paper itself

Abstract

background and purposeOral anticoagulants are needed in stroke patients with atrial fibrillation (AF) for the prevention of recurrent stroke. However, the risk of major events or bleeding may be greater in stroke patients than in those without, because the presence of cerebral atherosclerosis or small vessel disease may increase these risks. This study aimed to investigate the outcomes of apixaban-treated stroke patients with AF and assess whether these factors are associated with the outcome.

methodsThis was a sub-analysis of stroke patients with AF enrolled in a prospective, open-label, multicenter, post-marketing surveillance study in South Korea, who were treated with apixaban and underwent magnetic resonance imaging (MRI) (Clinical trial registration: NCT01885598).

resultsA total of 651 patients (mean age, 72.5±8.7 years) received apixaban for a mean duration of 82.7±37.4 weeks. Fifty-three bleeding events occurred in 39 patients (6.0%), and 10 (1.5%) experienced major bleeding. Seventeen patients (2.6%) had major events (stroke, n=15, 2.3%; all ischemic), systemic embolism (n=1, 0.2%), and death (n=3, 0.5%). MRI data showed no significant association between white matter ischemic changes and microbleeds, and major events or bleeding. Patients with cerebral atherosclerotic lesions had a higher rate of major events than those without (4.6% [n=10/219] vs. 1.7% [n=7/409], P=0.0357), which partly explains the increased prevalence of major outcomes in this group versus patients without stroke (0.7%, P=0.0002).

conclusionsApixaban is generally safe for patients with ischemic stroke. Increased primary outcomes in stroke patients may in part be attributed to the presence of cerebral atherosclerotic lesions, suggesting that further studies are needed to establish therapeutic strategies in this population.

Indexed as

ApixabanMagnetic resonance imagingStroke

Identifiers

PMID35135065
PMCPMC8829474
OpenAlexW4210801566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.